• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Zevra Therapeutics Inc.

    11/14/24 1:00:16 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZVRA alert in real time by email
    SC 13G 1 p24-3057sc13g.htm ZEVRA THERAPEUTICS, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.)*
     

    Zevra Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    488445206

    (CUSIP Number)
     

    September 30, 2024

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 6 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 48844520613GPage 2 of 6 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Woodline Partners LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    4,048,653

    6

    SHARED VOTING POWER

    - 0 -

    7

    SOLE DISPOSITIVE POWER

    4,048,653

    8

    SHARED DISPOSITIVE POWER

    - 0 -

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,048,653

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.7%

    12

    TYPE OF REPORTING PERSON

    IA

             

     

     

    CUSIP No. 48844520613GPage 3 of 6 Pages

     

    Item 1(a). NAME OF ISSUER.
       
      The name of the issuer is Zevra Therapeutics, Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 1180 Celebration Boulevard, Suite 103, Celebration, Florida 34747.

     

    Item 2(a) NAME OF PERSON FILING:
       
      This statement is filed by Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP (the "Woodline Fund"), with respect to the shares of Common Stock (as defined in Item 2(d) below) directly held by the Woodline Fund.
       
      The filing of this statement should not be construed as an admission that the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111.

     

    Item 2(c). CITIZENSHIP:
       
      Woodline Partners is a Delaware limited partnership.  

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common stock, par value $0.0001 per share (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER:
       
      488445206

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

     

     

    CUSIP No. 48844520613GPage 4 of 6 Pages

     

      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
      specify the type of institution:   _________________________________

     

    Item 4. OWNERSHIP.
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for the Reporting Person and is incorporated herein by reference.
       
      The percentage set forth herein is calculated based upon 52,617,789 shares of Common Stock outstanding as of August 12, 2024 as reported in the Company’s Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 14, 2024.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: o

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2. The Woodline Fund has right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

     

    CUSIP No. 48844520613GPage 5 of 6 Pages

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.
       
      The Reporting Person hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 48844520613GPage 6 of 6 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATED: November 14, 2024

     

    WOODLINE PARTNERS LP
         
         
    By: /s/ Erin Mullen  
    Name: Erin Mullen  
    Title: General Counsel & Chief Compliance Officer  
         

     

    Get the next $ZVRA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZVRA

    DatePrice TargetRatingAnalyst
    7/2/2025$26.00Buy
    H.C. Wainwright
    1/8/2025$25.00Overweight
    Cantor Fitzgerald
    10/7/2024$20.00Buy
    Guggenheim
    9/24/2024$17.00Mkt Outperform
    JMP Securities
    9/24/2024$18.00 → $25.00Buy
    Maxim Group
    4/2/2024$12.00 → $18.00Buy
    Maxim Group
    3/12/2024Outperform
    William Blair
    3/17/2023$12.00Buy
    Maxim Group
    More analyst ratings

    $ZVRA
    SEC Filings

    View All

    SEC Form 10-Q filed by Zevra Therapeutics Inc.

    10-Q - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

    8/12/25 5:24:42 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

    8/12/25 4:10:35 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Zevra Therapeutics Inc.

    8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

    5/29/25 4:42:38 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bode John B bought $45,825 worth of shares (5,000 units at $9.16), increasing direct ownership by 12% to 45,000 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    8/20/25 4:38:00 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal & Compliance Thompson Rahsaan sold $221,004 worth of shares (24,000 units at $9.21), decreasing direct ownership by 36% to 42,666 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    6/30/25 5:02:34 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal & Compliance Thompson Rahsaan converted options into 66,666 shares (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    6/24/25 5:28:38 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zevra Reports Second Quarter 2025 Financial Results and Corporate Update

    Q2 2025 net revenue of $25.9 million, driven by product net revenue of $21.8 million Completed sale of PRV for $150.0 million, bolstering the balance sheet as the Company executes on its commercial launches and development programs Submitted a Marketing Authorisation Application to the European Medicines Agency for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C Company to host conference call and webcast TODAY, August 12, 2025, at 4:30 p.m. ET CELEBRATION, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, t

    8/12/25 4:05:19 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

    CELEBRATION, Fla., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference in Boston, MA, on Wednesday, August 13, 2025, at 1:00 p.m. ET. Additionally, management will be available for one-on-one meetings with registered conference attendees. The live webcast will be accessible via "Events & Presentations" on the Investor Relations section of Zevra's website at investors.zevra.com.  About Zevra

    8/6/25 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

    CELEBRATION, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the second quarter 2025 on Tuesday, August 12, 2025, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day. A link to the audio webcast will be accessible on the "Events & Presentations" page in the Investor Relations section of Zevra's website at https://investors.zevra.com/. To join via telephone, please use the following dial-in information: (800) 245

    8/4/25 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bode John B bought $45,825 worth of shares (5,000 units at $9.16), increasing direct ownership by 12% to 45,000 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    8/20/25 4:38:00 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Watton Corey Michael bought $2,352 worth of shares (300 units at $7.84), increasing direct ownership by 20% to 1,800 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    3/31/25 8:05:01 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bode John B bought $79,624 worth of shares (10,000 units at $7.96), increasing direct ownership by 33% to 40,000 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    3/21/25 4:06:49 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Zevra Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $26.00

    7/2/25 7:59:19 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Zevra Therapeutics with a new price target

    Cantor Fitzgerald resumed coverage of Zevra Therapeutics with a rating of Overweight and set a new price target of $25.00

    1/8/25 8:49:26 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Zevra Therapeutics with a new price target

    Guggenheim initiated coverage of Zevra Therapeutics with a rating of Buy and set a new price target of $20.00

    10/7/24 8:28:23 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Leadership Updates

    Live Leadership Updates

    View All

    Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

    Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the Company's Board of Directors Board and Management Reaffirm Commitment to Driving Continued Growth and Progress Against Strategic Plan CELEBRATION, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) ("Zevra," or the "Company"), a commercial-stage company focused on providing therapies to people living with rare disease, announced that based on the final vote count certified by the independent Inspector of Elections following the Company's 2025 Annual Meeting of Stockholders (the "Annual Meeting"), stockholders have voted to re-elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the

    5/29/25 4:35:32 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics Expands Executive Leadership Team

    Rahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance Officer Alison Peters appointed as Chief People Officer CELEBRATION, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointments of Rahsaan W. Thompson as Chief Legal Officer, Secretary and Compliance Officer, and Alison Peters as Chief People Officer. Both Mr. Thompson and Ms. Peters bring deep expertise in building high-performing teams which will be essential to deliver success through the Company's next phase of growth. "We are thrilled to welcome both Rahsaan and Alison to the Zevra team as w

    6/25/24 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics' President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024

    CELEBRATION, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, Zevra's President and Chief Executive Officer, has issued a Letter to Stockholders providing a review of key accomplishments and outlook for 2024. Dear Stockholders, It is hard for me to believe that April 2024 marks six months since the start of my tenure as Zevra's President and Chief Executive Officer in October 2023. From that time, and even prior to my official start date, I began a listening tour, seeking feedback from many of Zevra's stakeholders – stockholders, investors, employees, patie

    4/29/24 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Financials

    Live finance-specific insights

    View All

    Zevra Reports Second Quarter 2025 Financial Results and Corporate Update

    Q2 2025 net revenue of $25.9 million, driven by product net revenue of $21.8 million Completed sale of PRV for $150.0 million, bolstering the balance sheet as the Company executes on its commercial launches and development programs Submitted a Marketing Authorisation Application to the European Medicines Agency for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C Company to host conference call and webcast TODAY, August 12, 2025, at 4:30 p.m. ET CELEBRATION, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, t

    8/12/25 4:05:19 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

    CELEBRATION, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the second quarter 2025 on Tuesday, August 12, 2025, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day. A link to the audio webcast will be accessible on the "Events & Presentations" page in the Investor Relations section of Zevra's website at https://investors.zevra.com/. To join via telephone, please use the following dial-in information: (800) 245

    8/4/25 7:30:00 AM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zevra Reports First Quarter 2025 Financial Results and Corporate Update

    Q1 2025 net revenue of $20.4 million, driven by product net revenue of $17.2 million Completed sale of PRV for gross proceeds of $150 million, positioning balance sheet to drive the Company's commercial launches and development programs Company to host conference call and webcast today, May 13, 2025, at 4:30 p.m. ET CELEBRATION, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the first quarter ended Mar. 31, 2025. "We are continuing Zevra's transformation into a patient-centric, commercial-

    5/13/25 4:05:00 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Zevra Therapeutics Inc.

    SC 13G - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

    11/14/24 1:00:16 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zevra Therapeutics Inc.

    SC 13G/A - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

    11/12/24 5:59:21 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zevra Therapeutics Inc.

    SC 13G/A - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

    11/4/24 2:15:20 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care